Front Line Therapy in Non-Small Cell Lung Cancer
Nick Thatcher
NICK THATCHER, Christie Hospital, Manchester
There is a proven benefit in survival if you give your patients cis-platinum based chemotherapy after resection for non-small cell lung cancer. Nick Thatcher emphasized this fact at the beginning of his talk in Turin about front line therapy for non-small cell lung cancer. He went on to discuss optimizing therapy with respect to histology, performance status and the addition of targeted agents. Peter Goodwin interviewed him about his recommendations.
There is a proven benefit in survival if you give your patients cis-platinum based chemotherapy after resection for non-small cell lung cancer. Nick Thatcher emphasized this fact at the beginning of his talk in Turin about front line therapy for non-small cell lung cancer. He went on to discuss optimizing therapy with respect to histology, performance status and the addition of targeted agents. Peter Goodwin interviewed him about his recommendations.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/080316_nick_thatcher.mp3]
